ACER News and Press, Acer Therapeutics Inc. From 08/10/21

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fin...

NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet...

Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (OTCQB:RLFTF) have submitted of a New Drug Application (NDA) to the FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs). Acer expects to receive FDA notification on the potential acceptance within 60...

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / August 9, 2021 / Acer Therapeutics Inc. (NASDAQ:ACER) (" Acer "), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medi...

Pinterest (NYSE:PINS) -20% on Q2 earnings release Cassava Sciences (NASDAQ:SAVA) -17% despite presenting 'positive' data on simufilam for Alzheimer's 360 DigiTech (NASDAQ:QFIN) -12%. Annovis Bio (NYSE:ANVS) -11%. Uxin (NASDAQ:UXIN) -11% on Q4 earnings release. Le...

LendingClub LC +38% on Q2 earnings. Cocrystal Pharma (NASDAQ:COCP) +26% SARS-CoV-2 3CL protease lead CDI-45205 demonstrates Broad-Spectrum activity against the SARS-CoV-2 Delta and Gamma Variants Flora Growth (NASDAQ:FLGC) +20%. Acer Therapeutics (NASDAQ:ACER) +21%. NanoVibroni...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re kicking off another busy day of trading with a dive into the biggest pre-market stock movers for Thursday. Source: Shutterstock We’re seeing a fair few companies this morning affect...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the thr...

Following a recent Type B meeting with the FDA, Acer Therapeutics (ACER), plans to conduct clinical trial of Edsivo (celiprolol) in patients with COL3A1+ vascular Ehlers-Danlos Syndrome (vEDS).EDS is an inherited disorder that affects the connective tissues in the body - p...